G. Zou et al. / Tetrahedron Letters 42 (2001) 7213–7215
7215
unrestricted grant from Taisho Pharmaceutical Co.,
Ltd.
K.; Duan, J. J.-W.; Barbosa, J.; Hull, K. G.; Iwashima,
M.; Qiu, Y.; Spoors, P. G.; Bertounesque, E.; Salvatore,
B. A. J. Org. Chem. 1998, 63, 7596–7597.
1
4. Non-commercial boronic acids were prepared by addition
of the corresponding Grignard reagent to tri-(iso-pro-
pyl)borate with aqueous isolation or by olefinic hydrobo-
ration with catecholborane: see, Fend, Z.; Hellberg, M.
Tetrahedron Lett. 2000, 41, 5813–5816.
References
1
2
. Review: Suzuki, A. J. Organomet. Chem. 1999, 576,
47–168.
1
. For example, see: (a) Littke, A. F.; Dai, C.; Fu, G. C. J.
Am. Chem. Soc. 2000, 122, 4020–4028; (b) Lobregat, V.;
Alcaraz, G.; Bienayme, H.; Vaultier, M. Chem. Commun.
1
5. For example: Pd(Ph P) , Pd(Cy P) , (dba) Pd /(t-Bu )P,
3
4
3
4
3
2
3
Ni(dppe)Cl , Pt(Ph P) were inferior. In some instances,
2
3
4
toluene as solvent gave comparable yields to those in
THF, but dioxane and DMF were less satisfactory.
6. See Tetrahedron Lett. 2001, 42, 7211–7212 for the appli-
cation of this methodology to the synthesis of bioactive
2
001, 817–818; (c) Kabalka, G. W.; Namboodiri, V.;
Wang, L. Chem. Commun. 2001, 775.
. (a) Miyaura, N.; Ishiyama, T.; Sasaki, H.; Ishikawa, M.;
Satoh, M.; Suzuki, A. J. Am. Chem. Soc. 1989, 111,
1
1
3
eicosanoid metabolites.
3
14–321; (b) Soderquist, J. A.; Santiago, B. Tetrahedron
1
7. Spectral data for 5: H NMR (400 MHz, CDCl ) l 6.40
3
Lett. 1990, 31, 5541–5542; (c) Ishiyama, T.; Miyaura, N.;
Suzuki, A. Synlett 1991, 687–688.
(
1
dt, J=1.5, 7.0 Hz, 1H), 6.31 (apparent q, J=7.0 Hz,
H), 3.01–3.07 (m, 1H), 2.91–2.98 (m, 1H), 2.39 (td,
4
5
. Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457–2483.
. Wolfe, J. P.; Singer, R. A.; Yang, B. H.; Buchwald, S. L.
J. Am. Chem. Soc. 1999, 121, 9550.
J=6.7, 1.5 Hz, 2H), 1.28–1.64 (m, 8H), 0.91 (t, J=7.0
13
Hz, 3H); C NMR (75 MHz, CDCl ) l 136.5, 84.9, 57.1,
3
1
5
4.8, 33.9, 31.7, 27.8, 26.3, 22.6, 14.1. Adduct 6:
H
6
. Srogl, J.; Allred, G. D.; Liebeskind, L. S. J. Am. Chem.
Soc. 1997, 119, 12376–12377.
NMR (400 MHz, CDCl ) l 5.50–5.58 (m, 1H), 5.38–5.48
3
(
(
m, 1H), 2.90–2.98 (m, 2H), 2.34–2.45 (m, 1H), 2.15–2.26
m, 1H), 2.07 (apparent q, J=6.4 Hz, 2H), 1.24–1.58 (m,
7. Cooke, G.; Augier de Cremiers, H.; Rotello, V. M.;
Tarbit, B.; Vanderstraeten, P. E. Tetrahedron 2001, 57,
1
2H), 0.92 (m, 6H). (1R,2R,3S,5R)-(−)-Pinanediol ester
2
787–2789.
. Chaumeil, H.; Signorella, S.; Le Drian, C. Tetrahedron
000, 56, 9655–9662.
. (a) Wright, S. W.; Hageman, D. L.; McClure, L. D. J.
Org. Chem. 1994, 59, 6095–6097; (b) Zhou, X.; Tse, M.
K.; Wan, T. S. M.; Chan, K. S. J. Org. Chem. 1996, 61,
1
of 17: H NMR (400 MHz, CDCl ) l 5.76–5.89 (m, 1H),
3
8
9
4
2
1
3
5
7
2
.90–5.05 (m, 2H), 4.25 (dd, J=2.0, 8.8 Hz, 1H), 2.29–
.39 (m, 1H), 2.18–2.26 (m, 1H), 2.02–2.12 (m, 3H),
.80–1.96 (m, 2H), 1.52 (quintet, J=8.0 Hz, 2H), 1.39 (s,
H), 1.29 (s, 3H), 1.12 (d, J=10.8 Hz, 1H), 0.81–0.88 (m,
2
13
H); C NMR (75 MHz, CDCl ) l 139.1, 114.6, 85.5,
3
3
590–3593; (c) Kabalka, G. W.; Pagni, R. M.; Hair, C.
7.7, 51.4, 39.7, 38.2, 36.5, 35.7, 28.8, 27.2, 26.6, 24.1,
M. Org. Lett. 1999, 1, 1423–1425.
1
3.7. (1R,2R,3S,5R)-(−)-Pinanediol ester of 21: H NMR
1
1
0. Molander, G. A.; Ito, T. Org. Lett. 2001, 3, 393–396.
1. Zou, G.; Falck, J. R. Tetrahedron Lett. 2001, 42, 5817–
819.
2. Sato, M.; Miyaura, N.; Suzuki, A. Chem. Lett. 1989,
405–1408.
3. Silver(I) oxide was previously applied to the cross-coup-
ling of methylboronic acid with highly reactive enol tri-
flates derived from b-ketoesters, but the scope of the
reaction was not further explored: Mu, Y.; Gibbs, R. A.
Tetrahedron Lett. 1995, 36, 5669–5672. For the use of
silver salts with cyclopropylboronic acid, see: Chen, H.;
Deng, M.-Z. J. Org. Chem. 2000, 65, 4444–4446. With
alkenylboronic acids, see: Smith, III, A. B.; Friestad, G.
(
400 MHz, CDCl ) l 4.25 (dd, J=2.4, 8.8 Hz, 1H),
3
2
.30–2.39 (m, 1H), 2.18–2.26 (m, 1H), 2.05 (apparent t,
J=5.2 Hz, 2H), 1.88–1.95 (m, 1H), 1.80–1.87 (m, 1H),
.38 (s, 3H), 1.29 (s, 3H), 1.17 (d, J=10.8 Hz, 1H), 0.85
5
1
1
1
1
13
(
s, 3H), 0.13 (s, 2H), 0.07 (s, 9H); C NMR (75 MHz,
CDCl ) l 85.3, 77.6, 51.5, 39.8, 38.3, 35.9, 29.0, 27.3,
26.7, 24.2, 0.61. Adduct 23: H NMR (300 MHz, CDCl
3
1
)
3
l 7.65 (dt, J=1.8, 7.5 Hz, 1H), 7.56–7.60 (m, 1H), 7.29
(apparent t, J=7.8 Hz, 1H), 7.16–7.22 (m, 1H), 2.57 (s,
13
3H), 2.14 (s, 2H), 0.02 (s, 9H); C NMR (75 MHz,
CDCl ) l 198.7, 141.4, 137.2, 132.9, 128.5, 127.7, 124.4,
3
27.2, 26.9, −1.78.